Company Overview

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's platform for peripheral nerve repair features a comprehensive portfolio of products, including Avance® Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; Axoguard® Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; Axoguard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments; Axoguard® Nerve Cap, a porcine submucosa ECM product used to protect a peripheral nerve end and separate the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and Avive® Soft Tissue Membrane, a processed human umbilical cord intended for surgical use as a resorbable soft tissue barrier. The Axogen portfolio of products is available in the United States, Canada, the United Kingdom, South Korea, and several other European and international countries.

Axogen, Inc. Reports Second Quarter 2020 Financial Results
Aug 5 2020, 4:01 PM EDT

Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
Jul 29 2020, 7:00 AM EDT

Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
Jul 22 2020, 7:00 AM EDT

Stock Overview

<table>
<thead>
<tr>
<th>Symbol</th>
<th>AXGN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>Nasdaq</td>
</tr>
<tr>
<td>Shares OS</td>
<td>38,672,871</td>
</tr>
<tr>
<td>Market Cap</td>
<td>$449.77M</td>
</tr>
<tr>
<td>Last Price</td>
<td>$11.63</td>
</tr>
<tr>
<td>52-Week Range</td>
<td>$7.16 - $18.84</td>
</tr>
</tbody>
</table>

08/13/2020 04:00 PM EDT

Investor Relations

Axogen, Inc.
13631 Progress Blvd
Suite 400
Alachua, FL 32615

investorrelations@axogeninc.com

Board of Directors

Karen Zaderej
Chairman, Chief Executive Officer, and President

Mark Gold M.D.
Director

Amy Wendell
Lead Director

Guido J. Neels
Director

Robert J. Rudelius
Director

Gregory G. Freitag
Special Counsel

Quentin S. Blackford
Director

Alan M. Levine
Director

Axogen, Inc.
13631 Progress Blvd
Suite 400
Alachua, FL 32615
Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company’s SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.